Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation

Therapy

Volumn 6, Issue 2, 2009, Pages 187-189

  Siddique, Aurangzeb ^a   Lip, Gregory Y H ^a   Shantsila, Eduard ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN DERIVATIVE; PLACEBO; PRASUGREL; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PATIENT COMPLIANCE; RISK REDUCTION; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 69449086327     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.6.2.187     Document Type: Editorial

References (6)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ et al.: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Int. Med. 5, 933-938 (1991).
2. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Int. Med. 7, 492-501 (1999).
3. Siddique A, Shantsila E, Lip GYL: The search for new anticoagulants: dabigatran etexilate. Therapy 5(6), 793-796 (2008).
4. Eriksson BI, Borris LC, Friedman RJ et al.; RECORD1 Study Group: rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008).
5. Kakkar AK, Brenner B, Dahl OE et al.; RECORD2 Investigators: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372, 31-39 (2008).
6. Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T: Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J. Thromb. Haemost. 2, 612-618 (2004).